^
    Back
    Association details:
    Biomarker:AR-regulated gene expression pathway signature
    Cancer:Triple Negative Breast Cancer
    Drug:Xtandi (enzalutamide) (Androgen receptor inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cell Press
    Title:

    Phase 2 Neoadjuvant Study of Enzalutamide and Paclitaxel in the Treatment of LAR-Enriched TNBC: Trial Results and Insight Into Arness

    Published date:
    06/28/2023
    Excerpt:
    We tested the combination of the AR inhibitor enzalutamide and weekly paclitaxel (ZT) as NAT for LAR-enriched TNBC....Pathologic complete response (pCR) or residual cancer burden-I (RCB-I) was achieved in 10 patients. ZT was safe, with no unexpected side effects….The AR-regulated gene expression pathway signature correlated with ZT therapy response as a potential predictive biomarker.
    Secondary therapy:
    paclitaxel
    DOI:
    http://dx.doi.org/10.2139/ssrn.4489787